Fiche société
Hoffmann-La Roche
Traitements, essais et publications liés.
Traitements117programmes
Essais65liés
Publications82liées
SourceDBlocale
Traitements
117| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| 13-PCV BoosterThis multicenter, randomized, open-label study will evaluate the immune response to vaccines (tetanus toxoid \[TT\]-containing adsorbed vaccine, 23-valent pneumococcal polysaccharide vaccine \[23-PPV\] either unboosted or boosted with 13-valent pneumococcal conjugate vaccine \[13-PCV\], influenza vaccine, keyhole limpet hemocyanin \[KLH\]) after administration of a dose of ocrelizumab (OCR) in participants with relapsing multiple sclerosis (RMS). | SEP | Phase 3 | United States, Canada | À vérifier | |
| 23-PPVThis multicenter, randomized, open-label study will evaluate the immune response to vaccines (tetanus toxoid \[TT\]-containing adsorbed vaccine, 23-valent pneumococcal polysaccharide vaccine \[23-PPV\] either unboosted or boosted with 13-valent pneumococcal conjugate vaccine \[13-PCV\], influenza vaccine, keyhole limpet hemocyanin \[KLH\]) after administration of a dose of ocrelizumab (OCR) in participants with relapsing multiple sclerosis (RMS). | SEP | Phase 3 | United States, Canada | À vérifier | |
| AbemaciclibThis is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy. | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, … | À vérifier |
| AcetaminophenThis study will evaluate the efficacy, safety, and pharmacokinetics of obinutuzumab compared with placebo in participants with International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 class III or IV lupus nephritis (LN) when added on to standard-of-care therapy consisting of mycophenolate mofetil (MMF) and corticosteroids. | Lupus | Phase 3 | À vérifier | United States, Argentina, Brazil, Colombia, France, Germany, Israel, Italy, … | À vérifier |
| Acetaminophen/ParacetamolThe purpose of this study is to evaluate the safety and efficacy of telcagepant in the treatment of acute migraine in participants with stable vascular disease. Acetaminophen/paracetamol (APAP) will be used as an active comparator in this study. The primary hypothesis of this study is that telcagepant 300 mg is superior to placebo. | Lupus, Migraine | Phase 2 | À vérifier | United States, Brazil, Canada, France, Italy, Mexico, Peru, Poland, … | À vérifier |
| AntihistamineThis is a randomized, double blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and PK of a higher dose of ocrelizumab per intravenous (IV) infusion every 24 weeks (Q24W) in participants with PPMS, in comparison to the approved 600 milligrams (mg) dose of ocrelizumab. | SEP | Phase 3 | À vérifier | United States, Argentina, Belgium, Brazil, Bulgaria, Canada, Denmark, France, … | À vérifier |
| CDK4/6iThis study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participants with endocrine-sensitive PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer (ABC). | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Brazil, Canada, China, France, Germany, … | À vérifier |
| delandistrogene moxeparvovecThis open-label, single-arm study will evaluate the safety and expression of delandistrogene moxeparvovec in participants with DMD. Participants will be in the study for approximately 264 weeks. | Myopathies | Phase 2 | À vérifier | Belgium, France, Germany, Italy, Spain, United Kingdom | À vérifier |
| Desloratadine given orallyThis study will evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity, and radiological and clinical effects of subcutaneous (SC) administration of ocrelizumab compared with the intravenous (IV) infusion of ocrelizumab in patients with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). | SEP | Phase 3 | À vérifier | United States, Brazil, Czechia, Italy, New Zealand, Poland, Spain, Turkey (Türkiye) | À vérifier |
| Dexamethasone given orallyThis study will evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity, and radiological and clinical effects of subcutaneous (SC) administration of ocrelizumab compared with the intravenous (IV) infusion of ocrelizumab in patients with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). | SEP | Phase 3 | À vérifier | United States, Brazil, Czechia, Italy, New Zealand, Poland, Spain, Turkey (Türkiye) | À vérifier |
| Diphenhydramine hydrochloride (HCl)This phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less than 18 with biopsy-confirmed proliferative lupus nephritis (LN). It will also evaluate open label safety and PK of obinutuzumab in pediatric participants (PP), aged 5 to \<12 with LN. | Lupus | Phase 2 | À vérifier | United States, Brazil, Canada, France, Italy, Mexico, Peru, Poland, … | À vérifier |
| Diphenhydramine IVThis study will evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity, and radiological and clinical effects of subcutaneous (SC) administration of ocrelizumab compared with the intravenous (IV) infusion of ocrelizumab in patients with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). | SEP | Phase 3 | À vérifier | United States, Brazil, Czechia, Italy, New Zealand, Poland, Spain, Turkey (Türkiye) | À vérifier |
| FenebrutinibA study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice or web-based response system (IxRS). 985 participants were enrolled and recruited globally. Participants who discontinue study medication early or discontinue from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study. | SEP | Phase 3 | Ralentissement de la progression | United States, Argentina, China, Dominican Republic, Finland, Georgia, Germany, Hong Kong, … | À vérifier |
| FulvestrantThis is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy. | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, … | À vérifier |
| GiredestrantThis study will evaluate the safety and efficacy of inavolisib combination therapies in participants with untreated, PIK3CA-mutated, Stage II-III, estrogen receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer (BC). | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, … | À vérifier |
| GlofitamabThis Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) in participants with relapsed or refractory aggressive B-cell Non-Hodgkin's lymphoma. The study utilizes an optimized steroid premedication regimen and monitoring schedule specifically designed to enable the administration of the treatment regimen in an outpatient setting. | Cancer | Phase 3 | À vérifier | United States, Australia, Brazil, Canada, China, France, Italy, Puerto Rico, … | À vérifier |
| InavolisibThis study will evaluate the safety and efficacy of inavolisib combination therapies in participants with untreated, PIK3CA-mutated, Stage II-III, estrogen receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer (BC). | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Brazil, Canada, China, France, Germany, … | À vérifier |
| Influenza VaccineThis multicenter, randomized, open-label study will evaluate the immune response to vaccines (tetanus toxoid \[TT\]-containing adsorbed vaccine, 23-valent pneumococcal polysaccharide vaccine \[23-PPV\] either unboosted or boosted with 13-valent pneumococcal conjugate vaccine \[13-PCV\], influenza vaccine, keyhole limpet hemocyanin \[KLH\]) after administration of a dose of ocrelizumab (OCR) in participants with relapsing multiple sclerosis (RMS). | SEP | Phase 3 | United States, Canada | À vérifier | |
| Interferon beta-1aTo evaluate the immunogenicity of a serum-free pre-formulated solution of Avonex when given to interferon beta naive patients with relapsing/remitting multiple sclerosis. | SEP | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Chile, … | À vérifier |
| KLHThis multicenter, randomized, open-label study will evaluate the immune response to vaccines (tetanus toxoid \[TT\]-containing adsorbed vaccine, 23-valent pneumococcal polysaccharide vaccine \[23-PPV\] either unboosted or boosted with 13-valent pneumococcal conjugate vaccine \[13-PCV\], influenza vaccine, keyhole limpet hemocyanin \[KLH\]) after administration of a dose of ocrelizumab (OCR) in participants with relapsing multiple sclerosis (RMS). | SEP | Phase 3 | United States, Canada | À vérifier | |
| LenalidomideThis phase II trial studies how well brentuximab vedotin and lenalidomide work in treating patients with stage IB-IVB T-cell lymphoma that have come back or do not respond to treatment. Monoclonal antibodies, such as brentuximab vedotin, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving brentuximab vedotin and lenalidomide may work better in treating patients with T-cell lymphoma. | Cancer | Phase 3 | À vérifier | United States, Australia, Brazil, Canada, China, France, Italy, Puerto Rico, … | À vérifier |
| LHRH AgonistThis is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy. | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, … | À vérifier |
| Methylprednisolone IVThis study will evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity, and radiological and clinical effects of subcutaneous (SC) administration of ocrelizumab compared with the intravenous (IV) infusion of ocrelizumab in patients with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). | SEP | Phase 3 | À vérifier | United States, Brazil, Czechia, Italy, New Zealand, Poland, Spain, Turkey (Türkiye) | À vérifier |
| MMFThis study will evaluate the efficacy, safety, and pharmacokinetics of obinutuzumab compared with placebo in participants with International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 class III or IV lupus nephritis (LN) when added on to standard-of-care therapy consisting of mycophenolate mofetil (MMF) and corticosteroids. | Lupus | Phase 3 | À vérifier | United States, Argentina, Brazil, Colombia, France, Germany, Israel, Italy, … | À vérifier |
| ObinutuzumabThis phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less than 18 with biopsy-confirmed proliferative lupus nephritis (LN). It will also evaluate open label safety and PK of obinutuzumab in pediatric participants (PP), aged 5 to \<12 with LN. | Cancer, Lupus | Phase 2 | À vérifier | United States, Brazil, Canada, France, Italy, Mexico, Peru, Poland, … | À vérifier |
| OCRThis multicenter, randomized, open-label study will evaluate the immune response to vaccines (tetanus toxoid \[TT\]-containing adsorbed vaccine, 23-valent pneumococcal polysaccharide vaccine \[23-PPV\] either unboosted or boosted with 13-valent pneumococcal conjugate vaccine \[13-PCV\], influenza vaccine, keyhole limpet hemocyanin \[KLH\]) after administration of a dose of ocrelizumab (OCR) in participants with relapsing multiple sclerosis (RMS). | SEP | Phase 3 | United States, Canada | À vérifier | |
| OcrelizumabA study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice or web-based response system (IxRS). 985 participants were enrolled and recruited globally. Participants who discontinue study medication early or discontinue from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study. | SEP | Phase 3 | Ralentissement de la progression | United States, Argentina, Australia, Austria, Brazil, Bulgaria, Canada, Chile, … | À vérifier |
| Ocrelizumab 300 mgThis national, open-label study is designed to give complementary efficacy, safety and patient reported outcomes (PROs) data in participants with active relapsing forms of MS. Participants will receive a maximum of 2 treatment cycles of ocrelizumab infusions: an initial dose of two 300 milligram (mg) infusions separated by 14 days followed by one single infusion of 600 mg ocrelizumab 24 weeks after the first infusion. Disease activity is determined by clinical relapses and/or Magnetic Resonance Imaging (MRI) activity. | SEP | Phase 4 | À vérifier | France | À vérifier |
| Ocrelizumab 600 mgThis national, open-label study is designed to give complementary efficacy, safety and patient reported outcomes (PROs) data in participants with active relapsing forms of MS. Participants will receive a maximum of 2 treatment cycles of ocrelizumab infusions: an initial dose of two 300 milligram (mg) infusions separated by 14 days followed by one single infusion of 600 mg ocrelizumab 24 weeks after the first infusion. Disease activity is determined by clinical relapses and/or Magnetic Resonance Imaging (MRI) activity. | SEP | Phase 4 | À vérifier | France | À vérifier |
| Ocrelizumab Co-formulated With rHuPH20The main purpose of this study is to evaluate the safety and tolerability of the ocrelizumab subcutaneous (SC) test formulation in participants with multiple sclerosis (MS). The study consists of two treatment phases: a dose-escalation and dose-continuation phase. Participants will receive single ascending doses of ocrelizumab SC during an initial dose-escalation phase, with the option to continue treatment with the selected dose of ocrelizumab SC in the dose-continuation phase. | SEP | Phase 3 | À vérifier | United States, Brazil, Mexico, United Kingdom | À vérifier |
| Ocrelizumab IVThis study will evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity, and radiological and clinical effects of subcutaneous (SC) administration of ocrelizumab compared with the intravenous (IV) infusion of ocrelizumab in patients with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). | SEP | Phase 3 | À vérifier | United States, Brazil, Czechia, Italy, New Zealand, Poland, Spain, Turkey (Türkiye) | À vérifier |
| Ocrelizumab Reference FormulationThe main purpose of this study is to assess the bioequivalence of ocrelizumab SC test formulation to the marketed ocrelizumab SC reference formulation in participants with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). The study consists of 2 phases: a controlled phase, where participants in each group will receive one dose of test or reference formulation and a continuation phase, where all participants in both groups will receive ocrelizumab SC test formulation. | SEP | Phase 2 | À vérifier | United States, Argentina, Brazil, France, Germany, Italy, Mexico, Poland, … | À vérifier |
| Ocrelizumab SCThis study will evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity, and radiological and clinical effects of subcutaneous (SC) administration of ocrelizumab compared with the intravenous (IV) infusion of ocrelizumab in patients with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). | SEP | Phase 3 | À vérifier | United States, Brazil, Czechia, Italy, New Zealand, Poland, Spain, Turkey (Türkiye) | À vérifier |
| Ocrelizumab Test FormulationThe main purpose of this study is to assess the bioequivalence of ocrelizumab SC test formulation to the marketed ocrelizumab SC reference formulation in participants with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). The study consists of 2 phases: a controlled phase, where participants in each group will receive one dose of test or reference formulation and a continuation phase, where all participants in both groups will receive ocrelizumab SC test formulation. | SEP | Phase 2 | À vérifier | United States, Argentina, Brazil, France, Germany, Italy, Mexico, Poland, … | À vérifier |
| OlesoximeDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | Phase 3 | À vérifier | Belgium, France, Germany, Spain, United Kingdom | À vérifier |
| olesoxime (TRO19622)This is a 24-week phase 1b, randomized, double-blind, placebo-controlled, parallel-group, multicenter safety study comparing the tolerance profile of olesoxime (495 mg, od) when administered on top of Interferon beta in patients with stable Relapsing Remitting Multiple Sclerosis. Patients will be randomly allocated to olesoxime (495 mg, od) or placebo in a 1:1 ratio. | SEP | Phase 1 | À vérifier | France | À vérifier |
| PalbociclibThis is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy. | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, … | À vérifier |
| PrasinezumabThe purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa. | Parkinson | Phase 2 | Traitement symptomatique | United States, Austria, Canada, France, Italy, Luxembourg, Poland, Spain, … | À vérifier |
| rHuPH20This study will evaluate the pharmacokinetics, safety and tolerability, and immunogenicity of ocrelizumab administered subcutaneously to participants with multiple sclerosis (MS). | SEP | Phase 1 | À vérifier | United States | À vérifier |
| RO7046015This multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous prasinezumab (RO7046015/PRX002) versus placebo over 52 weeks in participants with early Parkinson's Disease (PD) who are untreated or treated with monoamine oxidase B (MAO-B) inhibitors since baseline. The study will consist of three parts: a 52-week, double-blind, placebo-controlled treatment period (Part 1) after which eligible participants will continue into an all-participants-on-treatment blinded dose extension for an additional 52 weeks (Part 2). Participants who complete Part 2 (including the 12-week treatment-free follow up visit assessing long term safety and efficacy of RO7046015) will be offered participation in Part 3 open-label extension (all-participants-on-RO7046015-treatment) for an additional 520 weeks. | Parkinson | Phase 2 | À vérifier | United States, Austria, France, Germany, Spain | À vérifier |
| RO7121932 IVThe primary purpose of the study is to evaluate the safety and tolerability of a single-ascending intravenous (IV) dose (Part 1), a single-ascending subcutaneous (SC) dose (Part 2), and multiple ascending SC doses (Part 3), and multiple-ascending SC doses following a single IV dose (Part 4) of RO7121932 in participants with multiple sclerosis (MS). Only Parts 1 and 2 of the study will be conducted in the United States, whereas Parts 1, 2, 3, and 4 will be conducted in all other participating countries outside the United States. | SEP | Phase 1 | À vérifier | United States, Belgium, Canada, Germany, Israel, Italy, Moldova, Poland, … | À vérifier |
| RO7121932 SCThe primary purpose of the study is to evaluate the safety and tolerability of a single-ascending intravenous (IV) dose (Part 1), a single-ascending subcutaneous (SC) dose (Part 2), and multiple ascending SC doses (Part 3), and multiple-ascending SC doses following a single IV dose (Part 4) of RO7121932 in participants with multiple sclerosis (MS). Only Parts 1 and 2 of the study will be conducted in the United States, whereas Parts 1, 2, 3, and 4 will be conducted in all other participating countries outside the United States. | SEP | Phase 1 | À vérifier | United States, Belgium, Canada, Germany, Israel, Italy, Moldova, Poland, … | À vérifier |
| RO7126209The purpose of this study is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of multiple-ascending intravenous (IV) doses of RO7126209 in participants with prodromal or mild to moderate Alzheimer's disease (AD), who are amyloid positive based on amyloid positron emission tomography (PET) scan. | Alzheimer | Phase 1/2 | À vérifier | United States, Australia, Canada, Chile, Japan, Poland, South Korea, Spain, … | À vérifier |
| RO7204239The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and efficacy of RO7204239, a humanized monoclonal antibody that binds to human latent myostatin, in ambulant adult participants with facioscapulohumeral muscular dystrophy (FSHD). | Myopathies | Phase 2 | À vérifier | United States, Denmark, Italy, United Kingdom | À vérifier |
| RO7269162This clinical trial is recruiting people who either are at risk of AD - have build-up of beta-amyloid, but have no clinical symptoms, or with a diagnosis of mild cognitive impairment. People can take part if they have a certain level of plaques (beta-amyloid) in the brain, shown by a positron emission tomography (PET) scan, a medical imaging technique in which tracers are injected to visualize specific pathological processes in the brain. People who take part in this clinical trial (participants) will be given RO7269162 OR placebo for up to about 1 and a half years. The clinical trial team will see them every 3 weeks in the first 3 months and then every 6 weeks until the end of the trial. These hospital visits will include checks to see how the participant responds to the treatment and any side effects they may have. The total time of participation in the clinical trial will be 90 weeks. | Alzheimer | Phase 2 | Traitement symptomatique | Chile, Denmark, France, Germany, Italy, Poland, South Korea, Spain, … | À vérifier |
| RO7507062The purpose of this study is to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of RO7507062 in participants with systemic lupus erythematosus (SLE). The study will have 2 parts: Part 1 is a single ascending dose-finding (SAD) part and Part 2 is a dose escalation with fractionated dosing part. | Lupus | Phase 1 | À vérifier | Colombia, France, Germany, Malaysia, Mexico, Netherlands, Peru, Poland, … | À vérifier |
| RO7812653This study aims to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics following administration of RO7812653 in participants with eAD. | Alzheimer | Phase 1 | À vérifier | Canada, Netherlands, Spain, Sweden, United Kingdom | À vérifier |
| RO7845860The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and, pharmacodynamics (PD) of subcutaneously administered RO7845860 in participants with relapsing multiple sclerosis (RMS). | SEP | Phase 1 | À vérifier | À vérifier | |
| SatralizumabThe purpose of this study is to assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of satralizumab, a humanized anti-interleukin-6 receptor (aIL-6R) monoclonal antibody, in ambulatory and non-ambulatory participants with DMD aged ≥ 8 to \< 18 years old receiving corticosteroid therapy. | Myopathies | Phase 2 | À vérifier | United States, Denmark, Italy, Poland, Spain, Ukraine | À vérifier |
| TeriflunomideA study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible participants will be randomized in a 1:1 ratio to receive either fenebrutinib or teriflunomide. At the end of the double-blind treatment (DBT) phase (after disclosure of the DBT results), the Sponsor will determine whether or not to initiate the open-label extension (OLE) phase of the study. | SEP | Phase 3 | Ralentissement de la progression | United States, Argentina, China, Dominican Republic, Finland, Georgia, Germany, Hong Kong, … | À vérifier |
| TocilizumabThe purpose of this study is to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of RO7507062 in participants with systemic lupus erythematosus (SLE). The study will have 2 parts: Part 1 is a single ascending dose-finding (SAD) part and Part 2 is a dose escalation with fractionated dosing part. | Cancer, Épilepsie, Lupus | Phase 1 | À vérifier | Colombia, France, Germany, Malaysia, Mexico, Netherlands, Peru, Poland, … | À vérifier |
| TrontinemabThe purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD). | Alzheimer | Phase 3 | Traitement symptomatique | United States, Canada, China, United Kingdom | À vérifier |
| TT VaccineThis multicenter, randomized, open-label study will evaluate the immune response to vaccines (tetanus toxoid \[TT\]-containing adsorbed vaccine, 23-valent pneumococcal polysaccharide vaccine \[23-PPV\] either unboosted or boosted with 13-valent pneumococcal conjugate vaccine \[13-PCV\], influenza vaccine, keyhole limpet hemocyanin \[KLH\]) after administration of a dose of ocrelizumab (OCR) in participants with relapsing multiple sclerosis (RMS). | SEP | Phase 3 | United States, Canada | À vérifier | |
| OlesoximeDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | Phase 3 | À vérifier | Belgium, France, Germany, Spain, United Kingdom | À vérifier |
| FenebrutinibA study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice or web-based response system (IxRS). 985 participants were enrolled and recruited globally. Participants who discontinue study medication early or discontinue from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study. | SEP | Phase 3 | Ralentissement de la progression | United States, Argentina, Australia, Austria, Brazil, Bulgaria, Canada, Chile, Colombia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Mexico, North Macedonia, Peru, Poland, … | À vérifier |
| FenebrutinibA study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice or web-based response system (IxRS). 985 participants were enrolled and recruited globally. Participants who discontinue study medication early or discontinue from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study. | SEP | Phase 2 | Ralentissement de la progression | United States, Bosnia and Herzegovina, Croatia, Czechia, Serbia, Slovakia | À vérifier |
| FenebrutinibA study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice or web-based response system (IxRS). 985 participants were enrolled and recruited globally. Participants who discontinue study medication early or discontinue from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study. | SEP | Phase 3 | Ralentissement de la progression | United States, Austria, Brazil, Bulgaria, Canada, Denmark, France, Greece, Guatemala, India, Italy, Mexico, Poland, Russia, South Korea, Turkey (Türkiye), United Kingdom | À vérifier |
| FenebrutinibA study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice or web-based response system (IxRS). 985 participants were enrolled and recruited globally. Participants who discontinue study medication early or discontinue from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study. | SEP | Phase 3 | Ralentissement de la progression | United States, Argentina, China, Dominican Republic, Finland, Georgia, Germany, Hong Kong, Hungary, Italy, Kenya, Mexico, Netherlands, North Macedonia, Peru, Poland, Portugal, Russia, Serbia, Spain, … | À vérifier |
| FenebrutinibA study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice or web-based response system (IxRS). 985 participants were enrolled and recruited globally. Participants who discontinue study medication early or discontinue from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study. | SEP | Phase 2 | Ralentissement de la progression | Argentina, Brazil, Mexico, Poland, Portugal, Spain, Ukraine | À vérifier |
| OcrelizumabA study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice or web-based response system (IxRS). 985 participants were enrolled and recruited globally. Participants who discontinue study medication early or discontinue from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study. | SEP | Phase 3 | Ralentissement de la progression | United States, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Czechia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Lithuania, Mexico, Netherlands, New Zealand, Norway, … | À vérifier |
| OcrelizumabA study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice or web-based response system (IxRS). 985 participants were enrolled and recruited globally. Participants who discontinue study medication early or discontinue from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study. | SEP | Phase 3 | Ralentissement de la progression | France | À vérifier |
| OcrelizumabA study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice or web-based response system (IxRS). 985 participants were enrolled and recruited globally. Participants who discontinue study medication early or discontinue from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study. | SEP | À vérifier | Ralentissement de la progression | United States | À vérifier |
| OcrelizumabA study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice or web-based response system (IxRS). 985 participants were enrolled and recruited globally. Participants who discontinue study medication early or discontinue from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study. | SEP | À vérifier | Ralentissement de la progression | United States, Australia | À vérifier |
| TeriflunomideA study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible participants will be randomized in a 1:1 ratio to receive either fenebrutinib or teriflunomide. At the end of the double-blind treatment (DBT) phase (after disclosure of the DBT results), the Sponsor will determine whether or not to initiate the open-label extension (OLE) phase of the study. | SEP | Phase 3 | Ralentissement de la progression | France | À vérifier |
| Interferon beta-1aTo evaluate the immunogenicity of a serum-free pre-formulated solution of Avonex when given to interferon beta naive patients with relapsing/remitting multiple sclerosis. | SEP | Phase 2 | À vérifier | À vérifier | |
| OcrelizumabA study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice or web-based response system (IxRS). 985 participants were enrolled and recruited globally. Participants who discontinue study medication early or discontinue from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study. | SEP | À vérifier | Ralentissement de la progression | United States | À vérifier |
| RO7507062The purpose of this study is to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of RO7507062 in participants with systemic lupus erythematosus (SLE). The study will have 2 parts: Part 1 is a single ascending dose-finding (SAD) part and Part 2 is a dose escalation with fractionated dosing part. | Lupus | Phase 1 | À vérifier | Colombia, France, Germany, Malaysia, Mexico, Netherlands, Peru, Poland, South Africa, Spain, Taiwan, Thailand, United Kingdom | À vérifier |
| RO7204239The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and efficacy of RO7204239, a humanized monoclonal antibody that binds to human latent myostatin, in ambulant adult participants with facioscapulohumeral muscular dystrophy (FSHD). | Myopathies | Phase 2 | À vérifier | United States, Denmark, Italy, United Kingdom | À vérifier |
| OcrelizumabA study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice or web-based response system (IxRS). 985 participants were enrolled and recruited globally. Participants who discontinue study medication early or discontinue from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study. | SEP | Phase 4 | Ralentissement de la progression | United States | À vérifier |
| Ocrelizumab 300 mgThis national, open-label study is designed to give complementary efficacy, safety and patient reported outcomes (PROs) data in participants with active relapsing forms of MS. Participants will receive a maximum of 2 treatment cycles of ocrelizumab infusions: an initial dose of two 300 milligram (mg) infusions separated by 14 days followed by one single infusion of 600 mg ocrelizumab 24 weeks after the first infusion. Disease activity is determined by clinical relapses and/or Magnetic Resonance Imaging (MRI) activity. | SEP | Phase 4 | À vérifier | France | À vérifier |
| Interferon beta-1aTo evaluate the immunogenicity of a serum-free pre-formulated solution of Avonex when given to interferon beta naive patients with relapsing/remitting multiple sclerosis. | SEP | Phase 3 | À vérifier | United States, Argentina, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Croatia, Czechia, France, Germany, Ireland, Italy, Mexico, Norway, Poland, Russia, Slovakia, Spain, … | À vérifier |
| OcrelizumabA study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice or web-based response system (IxRS). 985 participants were enrolled and recruited globally. Participants who discontinue study medication early or discontinue from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study. | SEP | Phase 3 | Ralentissement de la progression | United States, Argentina, Belgium, Brazil, Bulgaria, Canada, Denmark, France, Germany, Greece, Hungary, Italy, Mexico, Peru, Poland, Portugal, Russia, Spain, Switzerland, Turkey (Türkiye), … | À vérifier |
| Ocrelizumab Test FormulationThe main purpose of this study is to assess the bioequivalence of ocrelizumab SC test formulation to the marketed ocrelizumab SC reference formulation in participants with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). The study consists of 2 phases: a controlled phase, where participants in each group will receive one dose of test or reference formulation and a continuation phase, where all participants in both groups will receive ocrelizumab SC test formulation. | SEP | Phase 2 | À vérifier | United States, Argentina, Brazil, France, Germany, Italy, Mexico, Poland, Spain | À vérifier |
| Ocrelizumab Co-formulated With rHuPH20The main purpose of this study is to evaluate the safety and tolerability of the ocrelizumab subcutaneous (SC) test formulation in participants with multiple sclerosis (MS). The study consists of two treatment phases: a dose-escalation and dose-continuation phase. Participants will receive single ascending doses of ocrelizumab SC during an initial dose-escalation phase, with the option to continue treatment with the selected dose of ocrelizumab SC in the dose-continuation phase. | SEP | Phase 1 | À vérifier | United States, Brazil, Mexico, United Kingdom | À vérifier |
| OcrelizumabA study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice or web-based response system (IxRS). 985 participants were enrolled and recruited globally. Participants who discontinue study medication early or discontinue from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study. | SEP | À vérifier | Ralentissement de la progression | Germany, Switzerland | À vérifier |
| RO7121932 IVThe primary purpose of the study is to evaluate the safety and tolerability of a single-ascending intravenous (IV) dose (Part 1), a single-ascending subcutaneous (SC) dose (Part 2), and multiple ascending SC doses (Part 3), and multiple-ascending SC doses following a single IV dose (Part 4) of RO7121932 in participants with multiple sclerosis (MS). Only Parts 1 and 2 of the study will be conducted in the United States, whereas Parts 1, 2, 3, and 4 will be conducted in all other participating countries outside the United States. | SEP | Phase 1 | À vérifier | United States, Belgium, Canada, Germany, Israel, Italy, Moldova, Poland, Portugal, Romania, Serbia, Spain | À vérifier |
| Ocrelizumab IVThis study will evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity, and radiological and clinical effects of subcutaneous (SC) administration of ocrelizumab compared with the intravenous (IV) infusion of ocrelizumab in patients with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). | SEP | Phase 3 | À vérifier | United States, Brazil, Czechia, Italy, New Zealand, Poland, Spain, Turkey (Türkiye) | À vérifier |
| OcrelizumabA study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice or web-based response system (IxRS). 985 participants were enrolled and recruited globally. Participants who discontinue study medication early or discontinue from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study. | SEP | Phase 4 | Ralentissement de la progression | United States | À vérifier |
| Interferon beta-1aTo evaluate the immunogenicity of a serum-free pre-formulated solution of Avonex when given to interferon beta naive patients with relapsing/remitting multiple sclerosis. | SEP | Phase 3 | À vérifier | United States, Australia, Austria, Brazil, Bulgaria, Canada, Croatia, Estonia, France, Germany, Italy, Latvia, Lithuania, Mexico, Netherlands, Poland, Puerto Rico, Romania, Russia, Serbia, … | À vérifier |
| RO7845860The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and, pharmacodynamics (PD) of subcutaneously administered RO7845860 in participants with relapsing multiple sclerosis (RMS). | SEP | Phase 1 | À vérifier | À vérifier | |
| OcrelizumabA study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice or web-based response system (IxRS). 985 participants were enrolled and recruited globally. Participants who discontinue study medication early or discontinue from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study. | SEP | Phase 3 | Ralentissement de la progression | United States, Argentina, Australia, Austria, Belarus, Belgium, Brazil, Bulgaria, Canada, Croatia, Czechia, Estonia, Finland, France, Germany, Hungary, Israel, Italy, Latvia, Lithuania, … | À vérifier |
| OcrelizumabA study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice or web-based response system (IxRS). 985 participants were enrolled and recruited globally. Participants who discontinue study medication early or discontinue from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study. | SEP | Phase 3 | Ralentissement de la progression | United States, Australia, Belgium, Bulgaria, Canada, Colombia, Croatia, France, Georgia, Italy, Lebanon, Mexico, Morocco, New Zealand, Poland, Portugal, Romania, Russia, Serbia, Spain, … | À vérifier |
| RO7269162This clinical trial is recruiting people who either are at risk of AD - have build-up of beta-amyloid, but have no clinical symptoms, or with a diagnosis of mild cognitive impairment. People can take part if they have a certain level of plaques (beta-amyloid) in the brain, shown by a positron emission tomography (PET) scan, a medical imaging technique in which tracers are injected to visualize specific pathological processes in the brain. People who take part in this clinical trial (participants) will be given RO7269162 OR placebo for up to about 1 and a half years. The clinical trial team will see them every 3 weeks in the first 3 months and then every 6 weeks until the end of the trial. These hospital visits will include checks to see how the participant responds to the treatment and any side effects they may have. The total time of participation in the clinical trial will be 90 weeks. | Alzheimer | Phase 2 | Traitement symptomatique | Chile, Denmark, France, Germany, Italy, Poland, South Korea, Spain, United Kingdom | À vérifier |
| ObinutuzumabThis phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less than 18 with biopsy-confirmed proliferative lupus nephritis (LN). It will also evaluate open label safety and PK of obinutuzumab in pediatric participants (PP), aged 5 to \<12 with LN. | Lupus | Phase 2 | À vérifier | United States, Brazil, Canada, France, Italy, Mexico, Peru, Poland, Russia, South Africa, Spain, United Kingdom | À vérifier |
| SatralizumabThe purpose of this study is to assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of satralizumab, a humanized anti-interleukin-6 receptor (aIL-6R) monoclonal antibody, in ambulatory and non-ambulatory participants with DMD aged ≥ 8 to \< 18 years old receiving corticosteroid therapy. | Myopathies | Phase 2 | À vérifier | United States, Denmark, Italy, Poland, Spain, Ukraine | À vérifier |
| delandistrogene moxeparvovecThis open-label, single-arm study will evaluate the safety and expression of delandistrogene moxeparvovec in participants with DMD. Participants will be in the study for approximately 264 weeks. | Myopathies | Phase 2 | À vérifier | Belgium, France, Germany, Italy, Spain, United Kingdom | À vérifier |
| Ocrelizumab Co-formulated With rHuPH20The main purpose of this study is to evaluate the safety and tolerability of the ocrelizumab subcutaneous (SC) test formulation in participants with multiple sclerosis (MS). The study consists of two treatment phases: a dose-escalation and dose-continuation phase. Participants will receive single ascending doses of ocrelizumab SC during an initial dose-escalation phase, with the option to continue treatment with the selected dose of ocrelizumab SC in the dose-continuation phase. | SEP | Phase 3 | À vérifier | À vérifier | |
| PrasinezumabThe purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa. | Parkinson | Phase 3 | Traitement symptomatique | United States, Australia, Austria, Brazil, Canada, China, Denmark, France, Germany, Italy, Mexico, Poland, Portugal, South Korea, Spain, Taiwan, United Kingdom | À vérifier |
| TrontinemabThe purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD). | Alzheimer | Phase 3 | Traitement symptomatique | United States, Argentina, Australia, Brazil, Canada, Denmark, France, Germany, Italy, Japan, Netherlands, Poland, South Korea, Spain, Switzerland, United Kingdom | À vérifier |
| TrontinemabThe purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD). | Alzheimer | Phase 3 | Traitement symptomatique | United States, Argentina, Brazil, Canada, China, France, Germany, Italy, Japan, Poland, Spain, Taiwan, United Kingdom | À vérifier |
| delandistrogene moxeparvovecThis open-label, single-arm study will evaluate the safety and expression of delandistrogene moxeparvovec in participants with DMD. Participants will be in the study for approximately 264 weeks. | Myopathies | Phase 1 | À vérifier | United States | À vérifier |
| 23-PPVThis multicenter, randomized, open-label study will evaluate the immune response to vaccines (tetanus toxoid \[TT\]-containing adsorbed vaccine, 23-valent pneumococcal polysaccharide vaccine \[23-PPV\] either unboosted or boosted with 13-valent pneumococcal conjugate vaccine \[13-PCV\], influenza vaccine, keyhole limpet hemocyanin \[KLH\]) after administration of a dose of ocrelizumab (OCR) in participants with relapsing multiple sclerosis (RMS). | SEP | Phase 3 | United States, Canada | À vérifier | |
| olesoxime (TRO19622)This is a 24-week phase 1b, randomized, double-blind, placebo-controlled, parallel-group, multicenter safety study comparing the tolerance profile of olesoxime (495 mg, od) when administered on top of Interferon beta in patients with stable Relapsing Remitting Multiple Sclerosis. Patients will be randomly allocated to olesoxime (495 mg, od) or placebo in a 1:1 ratio. | SEP | Phase 1 | À vérifier | France | À vérifier |
| ObinutuzumabThis phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less than 18 with biopsy-confirmed proliferative lupus nephritis (LN). It will also evaluate open label safety and PK of obinutuzumab in pediatric participants (PP), aged 5 to \<12 with LN. | Cancer | Phase 2 | À vérifier | United States, Australia, Canada, France, Germany, Italy, South Korea | À vérifier |
| OcrelizumabA study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice or web-based response system (IxRS). 985 participants were enrolled and recruited globally. Participants who discontinue study medication early or discontinue from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study. | SEP | Phase 3 | Ralentissement de la progression | United States, Argentina, Australia, Belgium, Brazil, Canada, Denmark, France, Germany, Greece, Hungary, Italy, Peru, Poland, Portugal, Russia, Spain, Switzerland, Turkey (Türkiye), Ukraine, … | À vérifier |
| ObinutuzumabThis phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less than 18 with biopsy-confirmed proliferative lupus nephritis (LN). It will also evaluate open label safety and PK of obinutuzumab in pediatric participants (PP), aged 5 to \<12 with LN. | Lupus | Phase 2 | À vérifier | France | À vérifier |
| ObinutuzumabThis phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less than 18 with biopsy-confirmed proliferative lupus nephritis (LN). It will also evaluate open label safety and PK of obinutuzumab in pediatric participants (PP), aged 5 to \<12 with LN. | Lupus | Phase 3 | À vérifier | United States, Argentina, Brazil, Colombia, France, Germany, Israel, Italy, Mexico, Peru, Poland, Russia, South Africa, Spain, United Kingdom | À vérifier |
| Interferon beta-1aTo evaluate the immunogenicity of a serum-free pre-formulated solution of Avonex when given to interferon beta naive patients with relapsing/remitting multiple sclerosis. | SEP | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Chile, Czechia, Estonia, Finland, France, Germany, Hungary, Israel, Italy, Latvia, Lithuania, Mexico, Netherlands, … | À vérifier |
| OcrelizumabA study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice or web-based response system (IxRS). 985 participants were enrolled and recruited globally. Participants who discontinue study medication early or discontinue from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study. | SEP | Phase 3 | Ralentissement de la progression | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Estonia, France, Germany, Greece, Hungary, India, Italy, Latvia, Mexico, Morocco, Poland, Portugal, Romania, … | À vérifier |
| OcrelizumabA study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice or web-based response system (IxRS). 985 participants were enrolled and recruited globally. Participants who discontinue study medication early or discontinue from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study. | SEP | À vérifier | Ralentissement de la progression | United States | À vérifier |
| InavolisibThis study will evaluate the safety and efficacy of inavolisib combination therapies in participants with untreated, PIK3CA-mutated, Stage II-III, estrogen receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer (BC). | Cancer | Phase 2 | À vérifier | United States, Argentina, Brazil, Canada, Germany, South Korea, Spain | À vérifier |
| OcrelizumabA study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice or web-based response system (IxRS). 985 participants were enrolled and recruited globally. Participants who discontinue study medication early or discontinue from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study. | SEP | Phase 4 | Ralentissement de la progression | Russia | À vérifier |
| OcrelizumabA study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice or web-based response system (IxRS). 985 participants were enrolled and recruited globally. Participants who discontinue study medication early or discontinue from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study. | SEP | Phase 3 | Ralentissement de la progression | Australia, Belgium, Czechia, Denmark, Estonia, Finland, France, Germany, Ireland, Italy, Netherlands, Norway, Spain, Sweden, Switzerland, Turkey (Türkiye), United Kingdom | À vérifier |
| RO7812653This study aims to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics following administration of RO7812653 in participants with eAD. | Alzheimer | Phase 1 | Traitement symptomatique | Canada, Netherlands, Spain, Sweden, United Kingdom | À vérifier |
| InavolisibThis study will evaluate the safety and efficacy of inavolisib combination therapies in participants with untreated, PIK3CA-mutated, Stage II-III, estrogen receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer (BC). | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Brazil, Canada, China, France, Germany, Italy, Japan, Mexico, Poland, Puerto Rico, South Africa, South Korea, Spain, Switzerland, Taiwan, Turkey (Türkiye), United Kingdom | À vérifier |
| ObinutuzumabThis phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less than 18 with biopsy-confirmed proliferative lupus nephritis (LN). It will also evaluate open label safety and PK of obinutuzumab in pediatric participants (PP), aged 5 to \<12 with LN. | Cancer | Phase 3 | À vérifier | United States, Australia, Brazil, Canada, China, France, Italy, Puerto Rico, South Korea, Spain, Sweden, Taiwan, United Kingdom | À vérifier |
| OcrelizumabA study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice or web-based response system (IxRS). 985 participants were enrolled and recruited globally. Participants who discontinue study medication early or discontinue from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study. | SEP | Phase 4 | Ralentissement de la progression | United States | À vérifier |
| OcrelizumabA study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice or web-based response system (IxRS). 985 participants were enrolled and recruited globally. Participants who discontinue study medication early or discontinue from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study. | SEP | Phase 1 | Ralentissement de la progression | United States | À vérifier |
| OcrelizumabA study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice or web-based response system (IxRS). 985 participants were enrolled and recruited globally. Participants who discontinue study medication early or discontinue from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study. | SEP | Phase 4 | Ralentissement de la progression | China | À vérifier |
| RO7046015This multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous prasinezumab (RO7046015/PRX002) versus placebo over 52 weeks in participants with early Parkinson's Disease (PD) who are untreated or treated with monoamine oxidase B (MAO-B) inhibitors since baseline. The study will consist of three parts: a 52-week, double-blind, placebo-controlled treatment period (Part 1) after which eligible participants will continue into an all-participants-on-treatment blinded dose extension for an additional 52 weeks (Part 2). Participants who complete Part 2 (including the 12-week treatment-free follow up visit assessing long term safety and efficacy of RO7046015) will be offered participation in Part 3 open-label extension (all-participants-on-RO7046015-treatment) for an additional 520 weeks. | Parkinson | Phase 2 | À vérifier | United States, Austria, France, Germany, Spain | À vérifier |
| TrontinemabThe purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD). | Alzheimer | Phase 3 | Ralentissement de la progression + Traitement symptomatique | United States, Canada, China, United Kingdom | À vérifier |
| ObinutuzumabThis phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less than 18 with biopsy-confirmed proliferative lupus nephritis (LN). It will also evaluate open label safety and PK of obinutuzumab in pediatric participants (PP), aged 5 to \<12 with LN. | Cancer | Phase 1 | À vérifier | United States, Australia, Germany, Israel, Italy | À vérifier |
| PrasinezumabThe purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa. | Parkinson | Phase 2 | Traitement symptomatique | United States, Austria, Canada, France, Italy, Luxembourg, Poland, Spain, United Kingdom | À vérifier |
| OcrelizumabA study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice or web-based response system (IxRS). 985 participants were enrolled and recruited globally. Participants who discontinue study medication early or discontinue from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study. | SEP | Phase 2 | Ralentissement de la progression | United States, Italy, Poland | À vérifier |
| OcrelizumabA study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (and placebo) or intravenous (IV) ocrelizumab (and placebo) in a blinded fashion through an interactive voice or web-based response system (IxRS). 985 participants were enrolled and recruited globally. Participants who discontinue study medication early or discontinue from the study will not be replaced. The Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study. | SEP | Phase 4 | Ralentissement de la progression | United States, Kenya, Puerto Rico | À vérifier |
| RO7126209The purpose of this study is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of multiple-ascending intravenous (IV) doses of RO7126209 in participants with prodromal or mild to moderate Alzheimer's disease (AD), who are amyloid positive based on amyloid positron emission tomography (PET) scan. | Alzheimer | Phase 1/2 | À vérifier | United States, Australia, Canada, Chile, Japan, Poland, South Korea, Spain, United Kingdom | À vérifier |
| GiredestrantThis study will evaluate the safety and efficacy of inavolisib combination therapies in participants with untreated, PIK3CA-mutated, Stage II-III, estrogen receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer (BC). | Cancer | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Costa Rica, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, India, Israel, … | À vérifier |
Essais cliniques
65| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Giredestrant | Cancer | Phase 3 | NCT06065748 | A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | ACTIVE_NOT_RECRUITING |
| RO7126209 | Alzheimer | Phase 1/2 | NCT04639050 | Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 4 | NCT04377555 | Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab | COMPLETED |
| Ocrelizumab | SEP | Phase 2 | NCT04075266 | A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Prasinezumab | Parkinson | Phase 2 | NCT04777331 | PADOVA — A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease | ACTIVE_NOT_RECRUITING |
| Obinutuzumab | Cancer | Phase 1 | NCT06291220 | 453 Ph1 CLL — A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | ACTIVE_NOT_RECRUITING |
| Trontinemab | Alzheimer | Phase 3 | NCT07717411 | PrevenTRON — A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease | RECRUITING |
| RO7046015 | Parkinson | Phase 2 | NCT03100149 | PASADENA — A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 4 | NCT07483450 | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 1 | NCT03972306 | A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis | COMPLETED |
| Ocrelizumab | SEP | Phase 4 | NCT04261790 | Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis | COMPLETED |
| Obinutuzumab | Cancer | Phase 3 | NCT06084936 | GLOBRYTE — A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | RECRUITING |
| Inavolisib | Cancer | Phase 3 | NCT06790693 | INAVO123 — A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer | RECRUITING |
| RO7812653 | Alzheimer | Phase 1 | NCT07234942 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD) | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT02861014 | A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) | COMPLETED |
| Ocrelizumab | SEP | Phase 4 | NCT05208840 | LEGATO — A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis | WITHDRAWN |
| Inavolisib | Cancer | Phase 2 | NCT07054190 | A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer | RECRUITING |
| Ocrelizumab | SEP | À vérifier | NCT02807285 | Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis | NO_LONGER_AVAILABLE |
| Ocrelizumab | SEP | Phase 3 | NCT05123703 | Operetta 2 — A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) | ACTIVE_NOT_RECRUITING |
| Interferon beta-1a | SEP | Phase 3 | NCT01247324 | A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis | COMPLETED |
| Obinutuzumab | Lupus | Phase 3 | NCT04221477 | REGENCY — A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis | ACTIVE_NOT_RECRUITING |
| Obinutuzumab | Lupus | Phase 2 | NCT07721363 | OBLUMEN — Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial | NOT_YET_RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT04544436 | MUSETTE — A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING |
| Obinutuzumab | Cancer | Phase 2 | NCT06806033 | A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma | RECRUITING |
| olesoxime (TRO19622) | SEP | Phase 1 | NCT01808885 | MSREPAIR — Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta. | COMPLETED |
| 23-PPV | SEP | Phase 3 | NCT02545868 | A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis | COMPLETED |
| delandistrogene moxeparvovec | Myopathies | Phase 1 | NCT04626674 | ENDEAVOR — A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort | RECRUITING |
| Mosunetuzumab | Lupus | Phase 2 | NCT07598396 | SOLUNA — A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis | RECRUITING |
| Trontinemab | Alzheimer | Phase 3 | NCT07169578 | TRONTIER 1 — A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | RECRUITING |
| Trontinemab | Alzheimer | Phase 3 | NCT07170150 | TRONTIER 2 — A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | RECRUITING |
| Prasinezumab | Parkinson | Phase 3 | NCT07174310 | PARAISO — A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease | RECRUITING |
| Ocrelizumab Co-formulated With rHuPH20 | SEP | Phase 3 | NCT07503340 | Operetta III — A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) | NOT_YET_RECRUITING |
| delandistrogene moxeparvovec | Myopathies | Phase 2 | NCT06128564 | ENVOL — A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD) | ACTIVE_NOT_RECRUITING |
| Satralizumab | Myopathies | Phase 2 | NCT06450639 | SHIELD DMD — A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD) | ACTIVE_NOT_RECRUITING |
| Obinutuzumab | Lupus | Phase 2 | NCT05039619 | POSTERITY — A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants | RECRUITING |
| RO7269162 | Alzheimer | Phase 2 | NCT06402838 | A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD) | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT04035005 | O'HAND — A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT05269004 | OLERO — A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| RO7845860 | SEP | Phase 1 | NCT07749157 | NOVA-BEAM — A Study of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple Sclerosis | NOT_YET_RECRUITING |
| Interferon beta-1a | SEP | Phase 3 | NCT01892722 | Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 4 | NCT05285891 | AMS05 — Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Ocrelizumab IV | SEP | Phase 3 | NCT05232825 | Ocarina II — A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis | COMPLETED |
| RO7121932 IV | SEP | Phase 1 | NCT05704361 | A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | À vérifier | NCT06780150 | SurfSubQ — A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS) | RECRUITING |
| Ocrelizumab Co-formulated With rHuPH20 | SEP | Phase 1 | NCT07667322 | OCARINA 3 — A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Ocrelizumab Test Formulation | SEP | Phase 2 | NCT07074886 | PORTAMENTO — A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT04548999 | GAVOTTE — A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) | ACTIVE_NOT_RECRUITING |
| Interferon beta-1a | SEP | Phase 3 | NCT01412333 | A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis | COMPLETED |
| Ocrelizumab 300 mg | SEP | Phase 4 | NCT03589105 | PRO-MSACTIVE — A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting | COMPLETED |
| Ocrelizumab | SEP | Phase 4 | NCT03853746 | Short-term B-cell Depletion in Relapsing Multiple Sclerosis | COMPLETED |
| RO7204239 | Myopathies | Phase 2 | NCT05548556 | MANOEUVRE — A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy | ACTIVE_NOT_RECRUITING |
| RO7507062 | Lupus | Phase 1 | NCT05835986 | A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | À vérifier | NCT03873389 | Ocrelizumab Effects on the Metabolome in MS | COMPLETED |
| Interferon beta-1a | SEP | Phase 2 | NCT00912860 | Immunogenicity and Safety Study of Serum-Free Avonex | COMPLETED |
| Teriflunomide | SEP | Phase 3 | NCT02587195 | TERICIS — A Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period | COMPLETED |
| Ocrelizumab | SEP | À vérifier | NCT04676555 | TIMIOS — Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis | COMPLETED |
| Ocrelizumab | SEP | À vérifier | NCT05131984 | Ocrelizumab Access by Socio-Economic Status | COMPLETED |
| Ocrelizumab | SEP | Phase 3 | NCT05210621 | CONSONANCE EX — LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT01194570 | ORATORIO — A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis | COMPLETED |
| Fenebrutinib | SEP | Phase 2 | NCT07161258 | FENerations1 — A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS) | RECRUITING |
| Fenebrutinib | SEP | Phase 3 | NCT04586010 | FENhance — A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING |
| Fenebrutinib | SEP | Phase 3 | NCT04586023 | FENhance 2 — Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING |
| Fenebrutinib | SEP | Phase 2 | NCT05119569 | FENopta — A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING |
| Fenebrutinib | SEP | Phase 3 | NCT04544449 | FENtrepid — A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Olesoxime | Sclérose latérale amyotrophique | Phase 3 | NCT00868166 | Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS | COMPLETED |
Publications
82| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Prasinezumab | Progress of Immunotherapies in Parkinson's Disease. | CNS neuroscience & therapeutics | ||
| Prasinezumab | The conundrum of alpha-synuclein antibody failures in Parkinson's disease: a narrative review of mechanisms and alternative metabolic hypotheses. | Therapeutic advances in neurological disorders | ||
| Prasinezumab | The Efficacy and Safety of Monoclonal Antibodies That Target Alpha-Synuclein in Parkinson's Disease: A Systematic Review. | Parkinson's disease | ||
| Diphenhydramine hydrochloride (HCl) | Assessment of an integrated therapeutic protocol for sheep with acute ruminal impaction: diagnostic and prognostic significance of rumen functions and hepatorenal biomarkers. | Frontiers in veterinary science | ||
| Obinutuzumab | Critical Reappraisal of Obinutuzumab Randomized Trials in Membranous Nephropathy. | Kidney international reports | ||
| Obinutuzumab | Response to the Letter to the Editor Entitled "Critical Reappraisal of Obinutuzumab Randomized Trials in Membranous Nephropathy". | Kidney international reports | ||
| Obinutuzumab | Impact of afucosylation strategy on antibody function: a comparative study of glycoengineered anti-CD20 antibodies Obinutuzumab and Obinutuzumab beta. | mAbs | ||
| Acetaminophen/Paracetamol | Ibuprofen vs. acetaminophen for acute mild-to-moderate pain management: A systematic review and meta-analysis of safety with a focus on paediatric populations. | British journal of clinical pharmacology | ||
| Acetaminophen/Paracetamol | Safety of acetylcysteine: a scoping review of iatrogenic overdose cases and their associated complications. | Clinical toxicology (Philadelphia, Pa.) | ||
| Tocilizumab | A curious case of generalized pruritus in giant cell arteritis. | JAAD case reports | ||
| Tocilizumab | A Case of Cytokine Release Syndrome (CRS) Related to Treatment With Lenvatinib Plus Pembrolizumab for Metastatic Clear Cell Renal Cell Carcinoma. | IJU case reports | ||
| Tocilizumab | An antibody-conjugated polymer nanoparticle that targets inflammatory site for abdominal aortic aneurysm antioxidant stress therapy. | Biomaterials advances | ||
| Lenalidomide | Neutrophil extracellular trap-related genes in PTCL: identification, prognosis and drug interaction prediction via bioinformatics-machine learning. | Hematology (Amsterdam, Netherlands) | ||
| olesoxime (TRO19622) | Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. | The Lancet. Neurology | ||
| olesoxime (TRO19622) | Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study. | Neurology and therapy | ||
| TT Vaccine | Dysregulation of Immune Regulatory Mediators and Reduced Antitetanus Toxoid Antibodies Are Associated with Submicroscopic Plasmodium Infection in Pregnancy in Colombia. | The American journal of tropical medicine and hygiene | ||
| TT Vaccine | Impact of dosing interval on immunogenicity following a heterologous typhoid conjugate vaccine booster in Nepalese children: An observational study. | The Journal of infection | ||
| OCR | Tsamba-stir-fried Tiebangchui: Attenuates the toxicity of raw Tiebangchui without compromising its analgesic efficacy in Caenorhabditis elegans through TRPV channel regulation. | Journal of ethnopharmacology | ||
| OCR | The MYBL2-GTSE1 axis promotes laryngeal squamous cell carcinoma progression by regulating PI3K/AKT-dependent glycolytic reprogramming. | Cancer biology & therapy | ||
| KLH | Harnessing Secondary Nucleation-Driven Supramolecular Bundled Fibers for Long-Range One-Dimensional Assembly of Semiconductor Nanocrystals. | Angewandte Chemie (International ed. in English) | ||
| KLH | Comment on "A systematic review: Brain age gap as a promising early diagnostic biomarker for Alzheimer's disease". | Journal of the neurological sciences | ||
| KLH | Sinomenine restrains the proliferation and hyperactivation of B lymphocytes partly by inhibiting interferon regulatory factor 5. | Journal of ethnopharmacology | ||
| Influenza Vaccine | Evaluation of influenza vaccine effectiveness among older adults in Jiaxing, China, 2022-2025: A test negative design-based study. | Human vaccines & immunotherapeutics | ||
| Influenza Vaccine | HPV vaccination scenario and parental willingness to pay among girls aged 9-14 y in the Yangtze River Delta, China. | Human vaccines & immunotherapeutics | ||
| Influenza Vaccine | Development of a pandemic H5N1 influenza vaccine using MDCK suspension cells: A scalable and efficient production platform. | Human vaccines & immunotherapeutics | ||
| 13-PCV Booster | Effect of probiotics on humoral responses to COVID-19 vaccination in older adults: a randomized, placebo-controlled trial (PIRATES-COV study). | Gut microbes | ||
| 13-PCV Booster | Parental preferences for immunization advisory clinic settings for children with special health care needs and associated factors in Shanghai: A cross-sectional study. | Human vaccines & immunotherapeutics | ||
| 13-PCV Booster | 8-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in children in Nepal (TyVOID): a prospective cohort follow-up study of the TyVAC Nepal randomised controlled trial. | The Lancet. Global health | ||
| 23-PPV | Cost-Utility Analysis of Early Vitrectomy vs Intravitreal Biopsy and Injection for Endophthalmitis. | Journal of vitreoretinal diseases | ||
| 23-PPV | Evaluating the Diagnostic Accuracy of Point-of-Care Ultrasound for Long Bone Fractures in the Emergency Department. | The Journal of emergency medicine | ||
| Desloratadine given orally | Does desloratadine alter the serum levels of montelukast when administered in a fixed-dose combination? | The Laryngoscope | ||
| Dexamethasone given orally | Interventions for idiopathic steroid-resistant nephrotic syndrome in children. | The Cochrane database of systematic reviews | ||
| Diphenhydramine IV | A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department. | Annals of emergency medicine | ||
| Methylprednisolone IV | Methylprednisolone for acute type A aortic dissection patients undergoing total arch replacement: Design and rationale of the Medal trial. | American heart journal | ||
| Ocrelizumab SC | Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study. | Therapeutic advances in neurological disorders | ||
| Ocrelizumab SC | Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data. | Journal of neurology, neurosurgery, and psychiatry | ||
| Ocrelizumab IV | Transitioning from intravenous to subcutaneous ocrelizumab in a high-volume infusion center: A time-and-motion-informed capacity and service-flow analysis. | Multiple sclerosis and related disorders | ||
| Antihistamine | Targeting oxidative stress, inflammation, and apoptosis: The protective role of desloratadine against vancomycin-induced testicular toxicity via the SIRT1/Nrf2/NF-κB axis. | Tissue & cell | ||
| Antihistamine | Clinical manifestations and management of Androctonus bicolor envenomation in a dog: A previously undescribed clinical case. | Toxicon : official journal of the International Society on Toxinology | ||
| Antihistamine | Repurposing loratadine to reverse colistin resistance in through targeting lipid A modification. | Emerging microbes & infections | ||
| Ocrelizumab 600 mg | Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. | The New England journal of medicine | ||
| Ocrelizumab 600 mg | Performance of Composite Endpoints Defining Progression Independent of Relapse Activity in Multiple Sclerosis. | Annals of clinical and translational neurology | ||
| Ocrelizumab 300 mg | Hepatic Safety of Adjunctive High-Dose Melatonin in Participants Receiving Ocrelizumab for Primary Progressive Multiple Sclerosis: Liver Toxicity Findings from a Phase I/II Randomised Clinical Trial (MELATOMS-1). | CNS drugs | ||
| delandistrogene moxeparvovec | Safety, Tolerability, and Efficacy of a Prophylactic Sirolimus Protocol for Patients Receiving Delandistrogene Moxeparvovec-Rokl Gene Therapy. | Human gene therapy | ||
| Satralizumab | Clinical Use of Interleukin-6 Blockade in Neuroimmunological Disorders. | Noro psikiyatri arsivi | ||
| Diphenhydramine hydrochloride (HCl) | Tracking Changes in Oral Health-Related Quality of Life Before, During, and After Radiotherapy in Tongue Squamous Cell Carcinoma: A Case Series. | Patient preference and adherence | ||
| Diphenhydramine hydrochloride (HCl) | Effect of ranitidine hydrochloride on water activity in ternary aqueous solutions containing drug and ionic liquid based on vapor liquid equilibria at 298.15 K. | Scientific reports | ||
| Obinutuzumab | Obinutuzumab β for aquaporin-4-positive neuromyelitis optica spectrum disorder: a phase 3 randomized controlled trial. | Nature medicine | ||
| Tocilizumab | Comparative Protective Effects of Anakinra and Tocilizumab in Experimental Ocular Ischemic Syndrome. | International journal of molecular sciences | ||
| Desloratadine given orally | Comparative Efficacy and Safety of Ebastine 20 mg, Ebastine 10 mg and Levocetirizine 5 mg in Acute Urticaria. | Journal of clinical and diagnostic research : JCDR | ||
| Desloratadine given orally | The effect of desloratadine on ischemia reperfusion induced oxidative and inflammatory renal injury in rats. | Renal failure | ||
| Dexamethasone given orally | Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer. | ESMO open | ||
| Dexamethasone given orally | Evaluation of the effects of A-PRF and oral dexamethasone use on postoperative complications in third molar extraction: a split-mouth randomized-controlled trial. | BMC oral health | ||
| Diphenhydramine IV | The Role of Cetirizine in the Changing Landscape of IV Antihistamines: A Narrative Review. | Advances in therapy | ||
| Diphenhydramine IV | A Case Report of Venezuelan Suntiger Tarantula (Psalmopoeus Irminia) Envenomation and Review of Tarantula Exposures. | The Journal of emergency medicine | ||
| Methylprednisolone IV | Probable Autoimmune Encephalitis Presenting With Catatonia in a Young Woman: A Case Report and Review of the Literature. | International journal of psychiatry in medicine | ||
| Methylprednisolone IV | Immune Checkpoint Inhibitor Therapy Induced Hypophysitis; A Tertiary Care Centre Experience; Highlighting Detection, Treatment Outcomes and Long Term Endocrinopathies and Recovery. | Clinical endocrinology | ||
| Ocrelizumab IV | Relative increase of memory B-cell subsets under s.c. B-cell-depleting therapies in multiple sclerosis. | Frontiers in immunology | ||
| Ocrelizumab IV | Subcutaneous Ocrelizumab for the Treatment of Relapsing Forms of Multiple Sclerosis: A Budget Impact Model. | PharmacoEconomics - open | ||
| Antihistamine | Characterization of adverse reactions to two antihistamine drugs: A descriptive analysis from WHO-VigiAccess. | PloS one | ||
| Antihistamine | Objective Sleep Assessment in Systemic Mastocytosis: Polysomnographic Findings from a Single-Center Observational Study. | Journal of clinical medicine | ||
| Ocrelizumab | Polymorphism Controls B-Cell Repopulation Kinetics in People With Multiple Sclerosis Treated With Ocrelizumab. | Neurology(R) neuroimmunology & neuroinflammation | ||
| Acetaminophen/Paracetamol | Improving detection of low-abundant pharmaceuticals and neurotransmitters via quadrupole isolation in MALDI mass spectrometry imaging. | Analytical and bioanalytical chemistry | ||
| Acetaminophen/Paracetamol | Membrane-Targeted Consequences of Acetaminophen Toxicity and Off-Target Effects of Antimicrobial Peptides on Host Cell Membranes. | International journal of molecular sciences | ||
| Ocrelizumab Test Formulation | The cost-utility analysis of adding ocrelizumab to the treatment plan for primary progressive multiple sclerosis in Iran. | Expert review of pharmacoeconomics & outcomes research | ||
| Ocrelizumab Test Formulation | Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b OCARINA I study. | Annals of clinical and translational neurology | ||
| Antihistamine | Omalizumab for Injection (Enyitan®) in Elderly Patients with Chronic Spontaneous Urticaria: Maintenance of Treatment Goals - A Six-Month Retrospective Follow-Up of Real-World Evidence. | International archives of allergy and immunology | ||
| Antihistamine | Anesthetic Management of an Elective Cesarean Section in a Patient With Systemic Mastocytosis and Latex Allergy, Complicated by Incidental Intraoperative Wolff-Parkinson-White Pre-excitation: A Case Report. | Cureus | ||
| Ocrelizumab 600 mg | Experience of using anti-CD 20 therapies in multiple sclerosis patients in Kenya. | Frontiers in neurology | ||
| Ocrelizumab 300 mg | Differential safety profiles of disease-modifying therapies in MS: Age- and sex-based analysis from a real-world cohort. | Multiple sclerosis and related disorders | ||
| Ocrelizumab 300 mg | Reinitiating ocrelizumab with a full 600 mg dose after extended treatment interruption: No increased risk of infusion-related reactions. | Multiple sclerosis journal - experimental, translational and clinical | ||
| Ocrelizumab | Efficacy and safety of mesenchymal stem cell transplantation for progressive multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials with clinical implications for patient stratification and treatment optimization. | Frontiers in immunology | ||
| Ocrelizumab | Ocrelizumab: Pediatric First Approval. | Paediatric drugs | ||
| Tocilizumab | Regulatory T cell modulation with selective CD28 blockade and IL-6 receptor antagonist in kidney transplant recipients: results of CTOT-24, a prospective clinical trial. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons | ||
| Ocrelizumab | Evaluation of the humoral response during ocrelizumab therapy in multiple sclerosis - an observational study. | Neurologia i neurochirurgia polska | ||
| Ocrelizumab | Ocrelizumab-induced colitis acutely managed with ciclosporin. | BMJ case reports | ||
| Teriflunomide | Real-world pharmacovigilance analysis of the association between multiple sclerosis disease-modifying therapies and intervertebral disc herniation. | Frontiers in pharmacology | ||
| Teriflunomide | Synthesis, characterization, and drug release evaluation of AHMA-PEG nanoparticles loaded with teriflunomide. | RSC advances | ||
| Teriflunomide | Cyanoacetylation of amines a traceless cyanoacetyl radical: synthetic access to teriflunomide. | Chemical communications (Cambridge, England) | ||
| Fenebrutinib | Time to Meaningful Clinical Response Across Approved and Emerging Therapies for Antihistamine-Refractory Chronic Spontaneous Urticaria: A Network Meta-Analysis. | Journal of clinical medicine | ||
| Olesoxime | Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial. | The Lancet. Neurology | ||
| Olesoxime | Apoptosis and motor deficits in SPG76 hereditary spastic paraplegia: Calpain 2 inhibition as therapeutic strategy. | Pharmacological research |